Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
Pancreatic cancer is one of the most lethal cancers, where curative surgical resections are rare and less than 5% of patients experience long-term survival. Despite numerous clinical trials, improvements in the systemic treatment of this disease have been limited. Gemcitabine, a nucleoside analogue,...
Main Authors: | Jennifer L. Spratlin, John R. Mackey |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/2/4/2044/ |
Similar Items
-
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
by: Jerome Raffenne, et al.
Published: (2019-11-01) -
Functional characterization of human equilibrative nucleoside transporter 1
by: Weiyun Huang, et al.
Published: (2016-12-01) -
Insight into the nucleoside transport and inhibition of human ENT1
by: Zhixiang Wu, et al.
Published: (2022-01-01) -
Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
by: Lenka N. C. Boyd, et al.
Published: (2023-10-01) -
Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
by: Cinzia Giacometti, et al.
Published: (2023-06-01)